Amarin Corp Plc (AMRN)

[jessellivermore]

biolover

JELIS showed stat sig reduction of CV events in the EPA vs placebo in the total group and stat sig CV event in the CAD secondary group (20% of total). It showed an 18% reduction in CV events in the non CAD group which was not stat sig. None of the groups showed survival...

The unrecognised falacy in JELIS was 60+% of the cohort was Japanese women who are arguably the longest living group on the planet. The incidence of CV events and deaths (only 63 deaths over the five year period in the 18.5K cohort) was too low too produce significant results...AMRN must get this fact out to the medical community...Primary care physicians may not fully understand lipid profiles, but the cardiologist and the AHA should understand JELIS better than they do.

The non-HDL-C is not that important and as a matter of fact, Lovaza also lowers the Non-HDL-C...Which is not the same thing as the LDL-C...Total cholesterol (TC) and HDL-C are determined by direct measurement....Non HDL-C is determined by subtracting HDL-C from TC.

LDL-C is determined indirectly by the Freidewald Equation which is... LDL-C = TC -HDL-C - TG/5.... TG is triglycerides
As you may note the reduction of TGs results in raising the LDL-C which is why the non rise in LDL-C was such a surprise. It also means AMR101 actually acts on the protein bound cholesterol in a posative way...Ie has a statin like effect...

Regards... ":>JL